Joseph Tarnowski joins CHO Plus as Chief Technology and Business Officer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Privately held CHO Plus, Inc. (www.CHO-Plus.com), an early-stage biotechnology innovation company, announced today the appointment of Joseph Tarnowski, PhD as Chief Technology and Business Officer. Joe previously held senior leadership positions at GSK, BMS, and ImClone, developing CMC and manufacturing capabilities for biopharmaceuticals and cell and gene therapies. During his career he led CMC teams that worked on clinical development programs across many therapeutic areas with many achieving regulatory approval and commercial launch, improving the lives of patients worldwide. Most recently he was Senior Vice President for Cell and Gene Therapy Platforms in Medicines Development and Supply for GSK’s Research and Development Division.
Joe Tarnowski commented: “I am excited to join CHO Plus to help Larry and his team advance the innovations they achieved through partnerships with therapeutics manufacturers and CDMOs, to unlock supply chain constraints, and to improve manufacturing efficiency.”
Larry Forman, CHO Plus Founder and CEO, added: ”I am delighted to welcome Joe as a key member of our leadership team at an exciting time for the company. Joe is widely respected for his scientific expertise as well as for his leadership skills throughout the biopharmaceutical industry. He will be instrumental in helping CHO Plus achieve broad adoption of its patented technologies.”
About CHO Plus, Inc.
CHO Plus was founded in 2014 with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic proteins for treating human disease (such as antibodies for the treatment of cancer). CHO Plus has developed patented cell engineering technology to increase the amount of protein-producing “machinery” (e.g. endoplasmic reticulum) within each cell. Current studies demonstrate productivity increases of up to 10-fold for therapeutic antibodies. This could lower pharmaceutical industry production costs by billions of dollars each year in aggregate, if widely adopted. In 2021 CHO Plus further applied its technology toward increasing productivity of cells used for production of virus vectors (such as AAV) for gene therapy. Current studies demonstrate cell productivity increases of over 15-fold for AAV, with up to 55% full capsids.
CHO Plus is located at the Johnson & Johnson Innovation – JLABS incubator in South San Francisco, CA.
For more information, visit www.CHO-Plus.com
Contacts
Larry Forman, CEO
+1 (845) 380-6993
Larry@CHO-Plus.com
